A randomised, concentration-controlled, comparison of standard (5-day) vs. prolonged (15-day) infusions of etoposide phosphate in small-cell lung cancer
Introduction
Etoposide is one of the most active agents in the treatment of small-cell lung cancer (SCLC), and has been used in a variety of schedules both as a single agent and in combination in a number of other tumour types [1] . The action of etoposide on cells is phase-specific and in clinical use schedule dependent, with response rates in SCLC with the same dose given as a single agent over one day or five days of 10% vs. 89% respectively [2] . Pharmacokinetic data from this and subsequent studies with five-and eight-day IV etoposide revealed that the time above which plasma etoposide exceeded low concentrations was significantly longer in responding patients, being most significant for time above 1, 1.5 and 2 ug/ml, while haematological toxicity (grade 3 or 4 neutropenia) was most significantly associated with the duration of exposure to concentrations > 3 ug/ml [3] .
Recent studies with prolonged oral schedules of etoposide have demonstrated activity in a number of tumour types, particularly SCLC [4, 5] , lymphoma [6] , germ-cell tumours [7] and ovarian cancer [8] . However, the absorption of oral etoposide is incomplete (60% bioavailability) and variable, both within and between patients [9] .
Consequently a number of investigators have turned to infusional etoposide, which achieves prolonged maintenance of low plasma concentrations without the variability of oral etoposide. A recent study from our research group reported the use of single agent etoposide infusions over five days targeting specific plasma concentrations using a therapeutic monitoring approach [10] . Patients were treated at target etoposide plasma concentrations of 2 ug/ml or 3 ug/ml for two cycles, with subsequent concentration escalation. Although response rates (typically achieved by the end of the second cycle of treatment) were similar between the two arms, there was significantly more myelosuppression in those patients targeted at 3 ug/ml, suggesting again that antitumour activity is retained at low concentrations of etoposide while bone marrow toxicity is significantly reduced. This hypothesis has not been tested in a randomised study.
Prolonged infusions of etoposide are difficult to carry out due to the poor solubility and stability of the drug. At an etoposide concentration of 1 mg/ml, infusion solutions are stable for less than 24 hours [11] . In the 5d infusional study previously described, bags were replaced daily and the drug was made up in volumes of 500 or 1000 mis to ensure stability. Infusions of longer than five days thus present considerable logistical problems. Etoposide phosphate (Bristol-Myers Squibb) is a new analogue of etoposide with much higher aqueous solubility (up to 20 mg/ml), thus requiring smaller dilution volumes and with a longer stability [12] . This compound has no cytotoxic activity itself, but once administered to the patient the phosphate group is rapidly removed to produce etoposide. The half-life of etoposide-phosphate disappearance, due to phosphate removal, in whole blood is around seven minutes, with pharmacokinetic studies after i.v. etoposide phosphate administration in man reporting an AUC ratio of etoposide phosphate to etoposide of <0.01 [13] . After i.v. dosing with etoposide phosphate the bioavailability of etoposide was 107%, indicating that with respect to plasma etoposide, i.v. etoposide phosphate and i.v. etoposide are bioequivalent [14] . The improved solubility, and bioequivalence, of etoposide phosphate thus makes prolonged infusional administration much easier for both patient and investigator, permitting treatment on an outpatient basis.
The study reported here was designed to determine the activity and toxicity of two schedules of etoposide phosphate, targeting plasma etoposide concentrations of 3 ug/ml over five days or 1 ug/ml over 15 days, in a randomised trial in patients with SCLC. Concentration was controlled by measuring plasma etoposide concentration during each cycle of treatment, with dose modification in individual patients to ensure target concentrations were achieved.
Patients and methods

Patients
Eligible patients had extensive small-cell lung cancer, based on standard staging procedures which included a full examination, chest X-ray, isotope bone scan and ultrasound or CT liver scan. Patients entered into the study were previously untreated, with an ECOG performance score of =£ 2, age ^ 75 years, normal renal function (serum creatinine < 130 umol/1), adequate hepatic function (serum AST $100 IU/1, bilirubin < 50 umol/1), and serum albumin 5= 30 g/1.
The study was approved by the local Research Ethics Committees of both participating centres, and all patients gave written, informed consent.
Treatment
All patients received single agent etoposide phosphate administered via a central venous access line (typically a Groshong line). Patients received prophylactic anticoagulation therapy with warfarin, Img daily per oral. On entry to the study patients were randomised to either a 5d infusion of etoposide phosphate targeting a plasma etoposide concentration of 3 ug/ml, or a 15d infusion of etoposide phosphate targeting a plasma etoposide concentration of 1 ug/ml.
Treatment consisted of a loading dose (30 mg/m 2 for patients in the 5d arm and 10 mg/m 2 for patients in the 15d arm), given in 100 ml saline over 30 minutes, immediately followed by the continuous infusion, at a starting dose of 3 mg/m 2 /hr in the 5d arm and 1 mg/m 2 /hr in the 15d arm. This was given in 250 ml saline, such that for 5d patients the 250 ml bag contained up to 900 mg etoposide phosphate, and lasted for the whole 5d infusion, and for 15d patients the bag The loading dose and infusional doses for cycles 2-6 were based on the preceding cycle, with the same final infusional dose carried over to the next cycle, and the loading dose calculated from the final infusional dose(mg/hr) xlO.
Non-5HT 3 anti-emetics were routinely used. Treatment was repeated every 21 days for up to six cycles, depending on tumour response. Patients with progressive disease were immediately removed from the study, and patients with stable disease and no symptomatic improvement were removed after three cycles of treatment. These patients received alternative chemotherapy, typically vincristine, adriamycin and cyclophosphamide.
The treatment and assessments are shown in schematic form in Figure 1 .
Treatment modification
Nadir blood counts were performed on days 8, 11, and 15 in both arms, and additionally on day 18 in the 15d arm. If the nadir neutrophil count was <0.5 x 1O 9 /1 or the nadir platelet count was <50 x 1O 9 /1 (both NCIC grade 4 toxicity) the target etoposide concentration was reduced by 25% (to 2.25 ug/ml in the 5d arm and 0.75 ug/ml in the 15d arm) for subsequent cycles.
For any non-haematological grade 3-4 toxicity attributable to treatment (excluding alopecia), the next cycle was delayed until resolution of toxicity and the target concentration reduced by 25%.
Treatment on cycles 2-6 only proceeded if on the day of treatment the neutrophil count was > 1.5 x 10 9 /l and platelet count > 150 x 10 9 /l. If counts were below these levels treatment was delayed by one week.
Therapeutic drug monitoring
For all patients treatment was commenced on the afternoon of day 1. On the morning of day 2 and day 4 in the 5d arm, or days 2, 5,8 and 11 in the 15d arm, an 8 ml blood sample was taken from a peripheral vein for determination of plasma etoposide, (using a modification of a previously published method) [15] . The sample was separated by centrifugation and 0.5 ml of plasma removed to a Pyrex tube, to which was added 3 mis chloroform and 50 ul of 50 ug/ml methyl, phenyl Table I . Pre-treatment characteristics (mean ± standard deviation) for patients randomised to receive 5d or 15d etoposide phosphate. hydantoin as internal standard. Di-phenyl hydantoin (phenytoin) was not used as an internal standard in this study in case any patient was receiving treatment with phenytoin as an anti-convulsant. Plasma concentrations were obtained within five to six hours of sampling to permit dose modification on the same day. Dose modification according to the measured plasma concentration was achieved using the following formula New CI dose (mg/hr) = Current CI dose (mg/hr) x target plasma concentration measured plasma concentration Dose modifications based on measured plasma concentration were only made if the concentration differed by more than 10% from the target concentration.
Tumour response
Patients completing at least one cycle of treatment were considered evaluable for tumour response, according to standard WHO criteria [16] .
Statistics
The study was designed to investigate a possible difference in haematological toxiciry and/or anti-tumour activity between a steady state etoposide concentration of 3 ug/ml for five days, compared to 1 ug/ml for 15 days. Forty patients in each arm were calculated as sufficient to detect a 30% difference in the number of patients with grade 3 or 4 neutropenia, or a 30% difference in response rate, at the 5% significance level and 80% power.
Comparisons between groups were made using the Mann-Whitney U-test, and frequency comparisons using a corrected Chi-squared test, both in Minitab (MINITAB Inc, State College, PA). Survival durations were calculated according to the Kaplan-Meier method [17] , using the log-rank test to determine significance [18] .
Results
The study was terminated after 29 patients had been entered, as an interim analysis at that point indicated a significant difference between the two arms with regard to both haematological toxicity and tumour response.
Pre-treatment characteristics for the 29 patients are shown in Table 1 the 5d arm and 15 to the 15d arm. The two groups were comparable with regard to age, performance status, albumin, haemoglobin, AST and creatinine. There were three patients in the 15d arm with serum alkaline phosphatase activity > 300 IU/1, compared to none in the 5d arm. However the difference in plasma alkaline phosphatase did not reach statistical significance (P = 0.10). Etoposide precipitate, indicating excessive degradation of etoposide phosphate, was not observed in any infusion bag.
Plasma etoposide monitoring
Data relating to plasma etoposide monitoring is shown in Table 2 . During the first cycle of treatment mean plasma etoposide on day 2 (prior to dose modification) was 3.88 ± 1.16 ug/ml in patients targeted at 3 ug/ml, and 1.18 ± 0.32 ug/ml in patients targeted at 1 ug/ml. This represents 129 ± 30% of the target concentration at 3 ug/ml, and 118 ± 32% of the target concentration at 1 ug/ml. On day 4, after dose modification on day 2 based on the plasma etoposide concentration, mean plasma etoposide concentrations were 3.04 ± 0.50 ug/ml (101 ± 17% of target) in the 5d arm, and 1.02 ± 0.13 ug/ml in the 15d arm (102 ± 12 % of target). For cycles 2-6, the mean plasma etoposide concentration was 104 ± 20% of target in the 5d arm (48 cycles, includes patients dose reduced to 2.25 ug/ml), and 103 ± 23% in the 15d arm (34 cycles, includes patient dose reduced to 0.75 ug/ml). To achieve the desired target plasma etoposide concentration the total dose administered during the first course of treatment (loading dose plus continuous infusion dose) was 599 mg (range 361-771 mg) in the 5d arm and 619 mg (range 357-810 mg) in the 15d arm.
Tumour response
Twenty-six patients completed at least one cycle of treatment and were evaluable for response and toxicity, 12 in the 5d arm and 14 in the 15d arm. Three patients did not complete the first cycle of treatment, two in the 5d arm and one in the 15d arm. Of the two in the 5d arm one patient reported feeling unwell one hour into the continuous infusion, with symptoms of shortness of breath, dizziness and anxiety. The infusion was stopped at two hours when these symptoms failed to resolve, and the patient was removed from the study. On subsequent questioning the patient reported experiencing similar episodes periodically during the preceding 12 months. The second patient completed the infusion and on day 7 had a WBC count of 7.0 x 10 9 /l (neutrophils 6.5 x 10 9 /l). On day 9 the patient reported feeling unwell to her family, having experienced diarrhoea and pyrexia. A general practitioner visited the patient at home and recommended admission to hospital; the patient declined and died at home on day 10. The patient not evaluable in the 15d arm died at home suddenly on day 9 of the first cycle, without any prior symptoms. The probable cause of death was reported as cardiac arrest, although post mortems were not performed in either of these cases of early death.
Although the number of patients entered into the study was small, there was a significant difference in response rates, with seven of 12 evaluable patients responding in the 5d arm (two CR, five PR, two SD, three PD, two NE), compared to two of 14 evaluable patients in the 15d arm (two PR, four SD, eight PD, one NE). This represents overall response rates of 58% (CI: 27%-85%) in the 5d arm and 14% (CI: 4%-42%) in the 15d arm (P = 0.04). Overall survival duration for all patients was 7.6 months, with a median of 8.3 months for patients in the 5d arm and 6.6 months for patients in the 15d arm (hazard ratio 1.11, P -0.82).
The two responding patients in the 15d arm both had very short duration's of response, relapsing at the end of three cycles and four cycles of treatment. In contrast, of the seven responding patients in the 5d arm, one relapsed during cycle 4 and the remaining six patients completed all six cycles of treatment. The only two patients to complete six cycles in the 15d arm both had stable disease, (but with symptomatic improvement). Of the eight patients in the 15d arm with progressive disease, one progressed after just one cycle of treatment, two after two cycles, four after three cycles and one after five cycles.
Toxicity
Haematological toxicity for the two arms of the study is shown in Table 3 , with data for the first cycle of treatment, when all patients were treated at 3 ug/ml or 1 ug/ml, and for all other cycles. Nadir blood cell counts during the first cycle of treatment in the 5d and 15d arms were 2.6 vs. 5.0 x 1O 9 /1 respectively for WBC's (P = 0.017), 1.4 vs. 3.3 x 1O 9 /1 for neutrophils (P = 0.013), 11.6 vs. 12.3 g/1 for haemoglobin (P = 0.34) and 165 vs. 241 x 10 9 /l for platelets (P -0.099). Six of 12 patients in the 5d arm experienced NCIC grade 3 or 4 neutropenia or leucopenia compared to 0/14 in the 15d arm (P = 0.004). Across all cycles in the 15d arm there was only one cycle associated with a neutropenia > NCIC grade 1 (grade 2 in cycle 3). During the same cycle the patient experienced grade 3 leucopenia, the only case of leucopenia or The target plasma etoposide concentration was reduced after the first cycle of treatment in four patients, three in the 5d arm (to 2.25 ug/ml) and one in the 15d arm (to 0.75 ug/ml). Of the three patients where target etoposide concentration was reduced on cycle 2 in the 5d arm, two were due to haematological toxicity, and one to grade 3 stomatitis. The patient in the 15d arm was concentration reduced due to grade 3 stomatitis. One patient in the 5d arm was concentration reduced on cycle 4 after haematological toxicity.
Non-haematological toxicities were generally mild. All patients experienced alopecia, typically of grade 2-3. Other toxicities, including stomatitis, nausea and diarrhoea were reported but were not common.
Discussion
The randomised trial described in this report was designed to investigate the activity and toxicity of 5d versus 15d continuous infusions of etoposide, but with the two treatment groups treated at specific plasma etoposide concentrations, rather than at the same dose. This concentration-controlled approach resulted in a similar systemic exposure between patients within each treatment group, and between the two treatment groups. This was an important component of the study as our group, and others, have reported relationships between specific plasma etoposide concentrations and both haematological toxicity and anti-tumour activity. Consequently, standardising systemic exposure between the two arms, rather than dose, would be expected to reduce pharmacodynamic variability between patients in the same treatment arm, due to the reduced pharmacokinetic variability, and allow firmer conclusions to be drawn regarding the activity of specific plasma etoposide concentrations.
The impact of this concentration controlled approach is apparent from the day 2 plasma etoposide concentrations, prior to any dose modification in individual patients, which ranged from 2.64-5.96 ug/ml in the 5d arm and 0.77-1.79 ug/ml in the 15d arm, with an overall interpatient variability of 30%. By day 4, after dose modifi-cation based on plasma etoposide concentration, this variability was reduced to around 15%, with the measured concentration on day 2 and day 4 being 3.88 ± 1.16 and 3.04 ± 0.50 ug/ml respectively in the 5d arm and 1.18 ± 0.32 and 1.02 ± 0.13 ug/ml in the 15d arm. This is in line with previous reports that the inter-patient pharmacokinetic variability after i.v. etoposide is around 30%, and intra-patient variability around 10%. It is important to note that in this study infusional doses were not changed if the measured plasma etoposide concentration was within 10% of the target concentration.
We have previously reported a scheduling study with single-agent etoposide in SCLC which closed early due to the low activity of a 500 mg/m 2 dose given over 24 hours, compared to the same dose given as 5 daily twohour infusions [2] . Although the current study was designed to enrol 80 patients (40 in each arm), this was also closed early after an interim analysis on the first 29 patients. With only 12 patients evaluable for response and toxicity in the 5d arm, and 14 in the 15d, there were significant differences with regard to both tumour response and haematological toxicity. Seven of 12 patients achieved a tumour response in the 5d arm compared to only two of 14 in the 15d arm (P -0.04), while six of 12 patients in the 5d arm experienced grade 3 or 4 leucopenia or neutropenia during the first cycle of treatment, compared to none of 12 patients in the 15d arm (P -0.004). Indeed during the first cycle at 1 ug/ml leucopenia or neutropenia was grade 0 or 1 in all patients.
It is clearly desirable to understand why a 15d exposure to lug/ml plasma etoposide had such low activity in this patient group. In recent years a number of other investigators have examined the relationship between steady-state plasma concentrations of etoposide, and its pharmacodynamic effects, with prolonged intravenous infusions or with hyper-fractionated oral dosing. Comparison of data from these studies is difficult as the tumour type, and previous treatments vary, but when considered together some apparent trends emerge. In the three day continuous infusion study of Ratain et al. [19] a 75% drop in leucocyte count, comparable to at least grade 3 leucopenia, was seen at a C ss of around 5 ug/ml [20] . In our own studies with continuous infusions over five days, haematological toxicity was dose limiting at 3 ug/ml plasma etoposide [10] , during continuous infusions for 14 days dose-limiting leucopenia was reported with doses which achieved a C ss of 2.2 ug/ml [21] , with 21-day hyper-fractionated oral etoposide a 75% drop in leukocytes was associated with an average etoposide concentration of 1.75 ug/ml [22] , and with 35-day continuous infusions dose-limiting toxicity was associated with C^ etoposide concentrations of > 1.5 ug/ml [23] . Although the number of patients in these studies were small, and the degree of previous treatment varied, the concentration of etoposide associated with toxicity consistently drops with increasing exposure duration. Additionally, although these studies were conducted in a mixture of small cell and nett- small-cell lung cancer patients, the concentration associated with tumour response also decreases consistently with increasing exposure, being 2 ug/ml over five days, > 1.2 ug/ml over 14 days, > 1.0 ug/ml over 21 days and >0.75 ug/ml over 35 days. This data is summarised graphically in Figure 2 for both haematological toxicity and tumour response.
With the caveats already mentioned, taken together these data suggest that there may be a 'therapeutic window' with etoposide which decreases with increasing exposure duration. Patients treated at 3 ug/ml over five days in the current study were well above the lower end of this window, with resultant anti-tumour activity and toxicity, whereas at 1 ug/ml over 15 days the target concentration was below concentrations which have subsequently been associated with response or toxicity with similar schedules. Clearly, based on data now available, patients in the prolonged arm of our study were undertreated when exposed to 1 ug/ml etoposide for 15 days. With a 15d duration of exposure a plasma concentration of around 1.75-2 ug/ml etoposide would be required to achieve anti-tumour activity, but limit haematological toxicity. It is important to note that this hypothetical therapeutic window relates only to the patient population from which it was derived (mainly SCLC), and may be quite different for other settings where etoposide is used, such as lymphoma or testicular teratoma.
There are a number of other reported studies which support this proposed therapeutic window. A recent study with continuous infusions of etoposide phosphate out to 42 days reported an MTD at 20 mg/m 2 /day, resulting in a steady-state plasma etoposide concentration of 1.14 ± 0.24 ug/ml [24] . In another recent study patients were treated with continuous infusional etoposide phosphate, with the dose modified to maintain a Cô f 1.3-1.8 ug/ml until toxicity (grade 3 or 4 leucopenia/ neutropenia). The average plasma etoposide concentration was around 1.6 ug/ml on days 2, 8 and 15 of the infusion, with the median duration of infusion being 21 days (range 8-41 days) [25] . Additionally, a phase I study with continuous infusion etoposide at 18-25 mg/m 2 /day in etoposide sensitive neoplasms reported therapy ranging from 21-560 days, with uninterrupted infusions of 21-153 days (treatment was interrupted for toxicity, and stopped if disease progression) [26] . Mean plasma etoposide concentration was 0.7 ug/ml, with only three patients having plasma etoposide > 1 ug/ml. Even at these low concentrations very prolonged infusions demonstrated anti-tumour activity, with responses in two of three patients with SCLC and five of 10 with non-Hodgkin's lymphoma.
These relationships may also shed some light on recent randomised trials with single agent oral etoposide in SCLC, both of which were closed to entry early because of worse response rates and/or survival compared to a control arm containing intravenous combination chemotherapy. In the first, extensive disease SCLC patients received either oral etoposide, 50 mg bd for 10 days of a 21-day cycle (« = 171), or intravenous combinations comprising either etoposide and vincristine or CAV (n -168) [27] . Overall response rates were 45% in the oral etoposide arm and 51% in the control arm (not significantly different), while overall survival showed a slight disadvantage to the oral arm (130 days vs. 183 days). Haematological toxicity with this schedule of etoposide was low, with only 18% of patients experiencing grade 2 or worse leucopenia, while grade 2 or worse anaemia occurred in 15% of patients with etoposide and 7% with the combination.
In the second study patients were randomised to receive 100 mg oral etoposide twice daily for 5 days, or intravenous chemotherapy consisting of alternating cycles of CAV/PE, repeated every 21 days for six cycles [28] . The study was closed after entry of 155 patients as overall response was inferior on the oral arm (33% vs. 46%, P < 0.01), as was one-year survival (9.8% vs. 19.3%) and progression free survival (3.6 months vs. 5.6 months). Overall toxicity was similar between the two arms, although at this dose and schedule of etoposide there were only two neutropenic episodes.
Based on our own data with 50 mg oral etoposide, average plasma concentration would have been around 1.2 ug/ml in the first of these studies, and around 2.4 ug/ml in the second [9] . For a part of each dosing interval the plasma concentration would have been below the therapeutic window suggested, particularly for the first study with a 50 mg dose.
The only other study which has compared standard and prolonged etoposide schedules in a randomised trial was conducted by the Cancer and Leukaemia group B [29] . Patients with extensive disease small cell lung cancer received either etoposide 130 mg/m 2 /day i.v. for three days and cisplatin 25 mg/m 2 /day i.v. for three days, repeated every 21 days for eight cycles, or etoposide 50 mg/m 2 /day for 21 days and cisplatin 33 mg/m 2 /day for three days repeated every 28 days for six cycles. The study was based on the assumption that at this dose the oral bioavailability of etoposide was 50%, such that the dose intensity across 24 weeks of treatment would be the same in each arm. However, bioavailability at this dose is around 60% [9] , and may be even higher [30] , such that the systemic etoposide dose in this trial was 390 mg/m 2 in the i.v. arm and 630 mg/m 2 , or higher, in the oral arm. There was no difference in either response rate or survival between the two arms, but haematological toxicity was significantly worse in the oral etoposide arm. In addition to the dose difference between the two treatments there is some evidence that the pharmacokinetics of etoposide may be affected by cisplatin, such that prior cisplatin exposure decreases etoposide clearance [31] . The systemic exposure difference between the two arms of the study would therefore be even greater. This study clearly demonstrated the lack of a dose, or systemic exposure, effect with regard to anti-tumour activity of etoposide in extensive small cell lung cancer when used in combination with cisplatin, but an effect on haematological toxicity. Subsequent pharmacokinetic analysis of data from this study found a relationship between plasma etoposide concentration after oral etoposide and haematological toxicity, but not tumour response [32] .
In recent years prolonged oral etoposide has shown activity in a number of settings, but this activity, with prolonged or standard oral schedules, may be compromised by two factors. Firstly, plasma concentrations may not be maintained within an active or therapeutic range for a large part of each dosing interval. The activity reported with these oral regimens suggests that peak concentrations clearly contribute to activity, but the consequence of plasma concentration falling below an active range is not yet clear, and maintaining concentration within the active range throughout the treatment period, with infusional or hyper-fractionated oral dosing, may be more effective. Secondly the bioavailability of oral etoposide is incomplete and variable [9, 33] , both within and between patients, such that toxicity is largely unpredictable. Many of the studies with 10-21-day schedules of low daily dose etoposide report grade 3 or 4 leucopenia or neutropenia in a significant proportion of patients, while in patients with low bioavailability activity is likely to be low. Although phase II reports suggested possibly improved activity with prolonged oral etoposide, there is still no data from randomised trials which have confirmed an advantage with prolonged dosing.
In summary the study reported herein indicates that the activity of a plasma etoposide concentration of 1 ug/ml maintained for 15 days is low, with regard to both anti-tumour effects and haematological toxicity. Antitumour activity, with haematological toxicity, was seen in patients treated at 3 ug/ml etoposide for five days. These, and other, data give us a clearer indication of the activity and toxicity of etoposide in different schedules and at different concentrations. However, the optimal schedule and concentration in specific tumour types is not certain. Specifically there is no data from randomised trials suggesting an advantage to more prolonged etoposide schedules. Further studies, particularly looking at pharmacokinetic/pharmacodynamic relationships are clearly required.
